Navigation Links
IDM Pharma's MEPACT(R) (Mifamurtide, L-MTP-PE) Receives Approval in Europe for Treatment of Patients with Non-Metastatic, Resectable Osteosarcoma
Date:3/9/2009

First New Agent Approved to Treat Osteosarcoma in More Than 20 Years

IRVINE, Calif., March 9 /PRNewswire-FirstCall/ -- IDM Pharma, Inc. (Nasdaq: IDMI) today announced that the European Commission has formally granted a Centralized marketing authorization for MEPACT(R) (mifamurtide, L-MTP-PE) for the treatment of patients with non-metastatic, resectable osteosarcoma, a rare and often fatal bone tumor that typically affects children and young adults. The Centralized marketing authorization allows MEPACT to be marketed in the 27 Member States of the European Union, as well as in Iceland, Liechtenstein and Norway. MEPACT was granted orphan medicinal product status in Europe in 2004 and under European pharmaceutical legislation is entitled to a period of 10 years market exclusivity in respect of the approved indication.

"Today's approval of MEPACT is a significant milestone for physicians and patients in Europe, giving them access to the first new osteosarcoma treatment option in 20 years," said Timothy P. Walbert, president and chief executive officer, IDM Pharma. "As our lead product candidate and first to receive approval, this is also a major milestone for IDM Pharma. We look forward to amending the New Drug Application (NDA) for mifamurtide in the United States and continuing to work toward bringing this important treatment to market in the U.S."

The approval was based on the Phase 3 MEPACT trial (INT-0133), a National Cancer Institute (NCI) funded cooperative group study conducted by the Children's Oncology Group (COG) and the largest study ever completed in osteosarcoma, enrolling approximately 800 patients. The study evaluated patient outcomes with the addition of MEPACT to three- or four-drug adjuvant chemotherapy (cisplatin, doxorubicin, and methotrexate with or without ifosfamide). Results demo
'/>"/>

SOURCE IDM Pharma, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine news :

1. Pharmasset to Present at Two Upcoming Investor Conferences
2. ePharmaSolutions Adds Several Industry Clinicians to its Rater Certification and Data Monitoring Department
3. Pharmasset to Present at the 27th Annual JPMorgan Healthcare Conference
4. Parkland Health & Hospital System Rolls Out Innovations PharmASSIST Technology Platform Across Nine Pharmacy Sites
5. PharmaSmart International, Inc. Redefines Blood Pressure Management through Technology and Pharmacy Focused Patient Services
6. Pharmasset to Webcast an Investor Event from the AASLD Meeting
7. Pharmasset Reports Financial Results for Quarter Ended March 31, 2008
8. Pharmasset to Present at the Rodman & Renshaw Healthcare Conference on Tuesday, May 20th
9. Pharmasset Appoints Patrick T. Higgins as Executive Vice President, Marketing & Sales
10. Pharmasset Presents R7128 14-Day Monotherapy Study Results for the Treatment of Chronic Hepatitis C
11. Pharmassets Underwriters Release Shares from Lock-Up
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... to artemisinin, the main drug to treat malaria, ... Plasmodium falciparum ( P. falciparum ) ... caused by a genetic mutation in the parasites. ... opposed to a standard three-day coursehas proved highly ... findings published today in the New England ...
(Date:7/30/2014)... Steven Reinberg HealthDay Reporter ... in the United States, at least 2,000 Americans die from ... Wednesday. Heat waves, heat stroke or sun stroke caused ... 2006 and 2010, according to the U.S. Centers for Disease ... severe loss of body heat -- accounted for 63 percent ...
(Date:7/30/2014)... It can happen in an instant: A small child pulls ... gets critically injured when the furniture tips over. "Every ... their homes and imagine what could tip over, fall off ... it becoming a reality," Dr. Alex Rosenau, president of the ... release. Between 2009 and 2011, roughly 43,000 people ended ...
(Date:7/30/2014)... 2014 SF Cable, distributor of the ... prices on the internet with guaranteed customer satisfaction announces ... and two colors. These lightning cords are MFI certified ... high quality SF Cable Lightning to USB Cables ... delivering faster charging and syncing. Compatible with the iPhone ...
(Date:7/30/2014)... York, New York (PRWEB) July 30, 2014 ... from uncontrollable brain bleeding has filed a Xarelto lawsuit ... by the blood thinner, Bernstein Liebhard LLP reports. According ... Court for the District of Vermont on July 25th, ... days when he suffered an irreversible brain bleed that ...
Breaking Medicine News(10 mins):Health News:Resistance to key malaria drug spreading at alarming rate in Southeast Asia 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 2Health News: Extreme Weather Kills 2,000 in U.S. Each Year: CDC 3Health News:Tip-Over Furniture Can Kill Kids 2Health News:SF Cable Delivers Certified Lightning Cable in Multiple Sizes and Colors 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Alleges Man’s Death from Uncontrollable Brain Bleeding Was Caused by Xarelto, Bernstein Liebhard LLP Reports 3
... to impact the lives of one million families by ... Calif., Feb. 9 Shaklee Corporation Chairman and CEO ... an opportunity that offers economic support to one million ... York City, NY on Feb. 10."Families are struggling to ...
... Burn Awareness Campaign to Teach Families How to Avoid This ... New research conducted by the national nonprofit Home Safety Council ... percent) agree that there are actions they could take to ... (44 percent) say they haven,t done so because they don,t ...
... opioid drugs can pose risks even for patients, agency ... U.S. Food and Drug Administration announced plans Monday to ... by requiring manufacturers of certain opioid drugs to help ... the medications. , The FDA said it has sent ...
... disease, cancer , , MONDAY, Feb. 9 (HealthDay News) -- ... researchers find no evidence that multivitamin use helps older ... two killers of women, respectively. , "Women can be ... do no harm, but they also seem to confer ...
... Global Prevention Network(TM) as New York AffiliateDALLAS and NEW ... the leader in disease prevention services, has signed an ... jointly participate in preventive medicine programs in New York ... New York affiliate in The Global Prevention Network (TM) ...
... The Department of Veterans Affairs (VA) is calling for ... -- from March 8 to 14 at all medical centers ... standards for patient safety."The safety of our patients is our ... Under Secretary for Health. "Therefore, I am ordering all of ...
Cached Medicine News:Health News:Shaklee Hits the Road with its Infinite Possibilities Tour in New York, NY 2Health News:American Families Unaware of Burn Dangers at Home 2Health News:American Families Unaware of Burn Dangers at Home 3Health News:American Families Unaware of Burn Dangers at Home 4Health News:FDA Seeks Better Regulation of Painkillers 2Health News:Vitamins Do Older Women Little Good 2Health News:Vitamins Do Older Women Little Good 3Health News:U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services 2Health News:U.S. Preventive Medicine(R), The Mount Sinai Medical Center Sign Affiliation Agreement to Jointly Deliver Preventive Medicine Services 3
(Date:7/30/2014)... SCHOFIELD, Wis. , July 30, 2014 /PRNewswire/ ... researcher, developer, and marketer of over-the-counter (OTC) medicinal ... is rebranding the LipiGesic ® M name along with ... will be replaced with the trademarked name MigraPure ... and color palette of PuraMed,s homeopathic, natural migraine ...
(Date:7/30/2014)... 30, 2014  El Camino Hospital, a leader in ... utilizing the Leaf Patient Monitoring system to help prevent ... of patients susceptible to bed sores. The ... study of the system, which showed dramatic improvement in ... regularly is the one of the most effect ways ...
(Date:7/30/2014)... -- InnoPharma, Inc. today announced the first generic launch of ... injection), in Canada.  Olanzapine is indicated for the rapid ... schizophrenia or bipolar I mania. As the ... into an agreement with Sandoz Canada Inc., pursuant to ... market and distribute Olanzapine Injection in Canada ...
Breaking Medicine Technology:PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 2PuraMed BioScience Rebrands its Natural Migraine Relief Medication, LipiGesic M 3El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 2El Camino Hospital Utilizes Cutting-Edge Leaf Patient Monitor System to Help Reduce Risk of Pressure Ulcers 3InnoPharma Announces Launch of Olanzapine for Injection, 10mg/vial in Canada 2
... ... ... ... ...
... ... ... ... ...
Cached Medicine Technology:Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 2Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 3Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 4Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 5Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 6Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 7Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 8Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 9Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 10Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 11Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 12Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 13Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 14Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 15Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 16Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 17Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 18Par Pharmaceutical Companies Reports Adjusted EPS of $0.65 for Fourth Quarter 2009 19Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 2Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 3Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 4Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 5Zargis StethAssist & Zargis Cardioscan Cleared for Sale in Australia 6
... Small Bone Power System combines precision ... under the most exacting conditions. The ... small bone osteotomies and oral/maxillofacial procedures ... Length Available), Oscillating Saw (Extended Length ...
... The Hall® Surgical E9000® System ... offers multiple electric handpieces specifically designed ... and Oral/Maxillofacial Surgery. The E9000 System ... console and 3 specialized handpieces designed ...
... USA™ Battery Tester is ... efficiently determine if your ... Extended Run, Stryker® 2115, ... Packs contain adequate charge ...
... offers a comprehensive line of high speed ... piece construction method that minimizes breakage. Using ... polished to create the sharpest edge possible, ... procedure., ,Our high speed cutters come ...
Medicine Products: